BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung CancerSun Min Lim, Sang-Yoon Lee|Clinical Cancer Research|2023Cited by 72
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel W. Neal, Thomas Newsom-Davis, Sang‐We Kim et al.|Journal of Clinical Oncology|2024Cited by 57
Lack of ROS1 Gene Rearrangement in Glioblastoma MultiformeSun Min Lim, Se Hoon Kim|PLoS ONE|2015Cited by 6